THE SHORT ANSWER
High-Performance Science Teams™ helps internal manufacturing and technical operations teams at therapeutics companies process and analytical development, manufacturing, MSAT, QC, QA, supply chain, and external manufacturing, operate as one team from clinical supply to commercial launch. It targets the behaviors behind late CMC surprises, inspection-readiness gaps, and CDMO relationships that drift, the issues that increasingly decide approval timelines.
Why is manufacturing now the critical path to approval?
For most of a program’s life, CMC runs in the background. Then the pivotal readout lands, the BLA or NDA timeline locks, and technical operations becomes the critical path overnight — process performance qualification, comparability, commercial-scale validation, and pre-approval inspection readiness all at once.
FDA’s own letters show how often that goes wrong. A peer-reviewed Johns Hopkins analysis of complete response letters for 43 novel therapeutics that were ultimately approved between 2020 and 2024 found manufacturing deficiencies were the most common problem: 65% of letters cited facility issues and 51% cited CMC issues, more than efficacy or safety. The median time from CRL to eventual approval was 1.28 years (Dilek et al., Therapeutic Innovation & Regulatory Science, 2026).
Facility findings and CMC gaps are technical on paper. In practice, many start as team problems: data that didn’t move between functions, risks that surfaced late, and decisions no one clearly owned.
What does team dysfunction look like in biotech technical operations?
- R&D culture meets GMP reality. Teams that grew up in discovery treat documentation, change control, and deviations as paperwork — until a mock inspection shows otherwise.
- Process development versus manufacturing. PD optimizes the process; manufacturing inherits it at scale. Comparability and scale-up questions surface during engineering runs instead of in design.
- Quality as the gate at the end. QA and QC review what operations already decided, so issues are found at batch disposition or in the CMC module draft, not when they were cheap to fix.
- CMC timelines that don’t match clinical timelines. Clinical development plans the readout; technical operations learns the filing date secondhand and compresses PPQ to fit.
- External manufacturing drift. In hybrid models, the CDMO relationship is owned by one person. Tech transfer, person-in-plant oversight, and quality agreements live in silos, and the sponsor hears about problems late.
- Hiring faster than norms can form. A new facility or launch ramp doubles headcount, and decision rights, escalation paths, and handoffs never get written down.
Why don’t new systems, consultants, or a bigger team fix it?
Therapeutics companies reach for vertical fixes when CMC gets tight: a new QMS or LIMS, an inspection-readiness consultant, a reorganization under a new Chief Technical Officer, more headcount. Each has its place. A mock inspection finds the gaps; it doesn’t change how process development, manufacturing, and QA work together to close them.
The pattern behind most CMC surprises is horizontal information and accountability that don’t cross functional lines and it needs a horizontal fix.
How does High-Performance Science Teams™ work for manufacturing teams?
The program applies Guttman Development Strategies’ horizontal high-performance team model to technical operations leadership and cross-functional CMC teams, working on live programs, live filings, and live CDMO relationships.
| CMC-risk pattern | Root behavior | What HPT installs |
| Late comparability and scale-up surprises | PD and manufacturing goals misaligned | Joint PD–MSAT–manufacturing ownership of scale-up and transfer readiness |
| Issues found at QA review | Quality brought in after decisions | QA and QC seated in program decisions early, with an explicit protocol for disagreement |
| Compressed PPQ and filing timelines | CMC and clinical plans built separately | A shared integrated timeline with named decision owners across clinical, regulatory, and technical operations |
| CDMO problems discovered late | One-person ownership of external partners | Cross-functional external-manufacturing team with early-warning norms and shared accountability |
| Inspection-readiness gaps | GMP habits not yet team norms | Peer accountability for documentation, deviation, and change-control discipline |
How does this fit with inspection readiness and quality systems?
High-Performance Science Teams™ does not replace your QMS, regulatory CMC strategy, or mock-inspection program. It changes how the people using them share information, raise risk, and make decisions, which is what inspectors see when they interview your team.
Who is it for?
Chief Technical Officers, SVPs and VPs of Technical Operations, Manufacturing, CMC, Quality, and Supply Chain, site heads, and CEOs and CHROs at clinical- and commercial-stage biotech and therapeutics companies especially those preparing a BLA or NDA, bringing an in-house GMP facility online, moving from clinical to commercial supply, or managing a hybrid in-house and CDMO network.
How do we get started?
Start with the Science Team 360™, a short, confidential team-level diagnostic that shows exactly where decision rights, alignment, and accountability are breaking down inside your technical operations team. You get a readout before anyone commits to a full engagement.
Request a Science Team 360™ conversation at bench2business.bio.
Frequently asked questions
Why do manufacturing issues delay FDA approval?
In a Johns Hopkins analysis of complete response letters for novel therapeutics ultimately approved in 2020–2024, facility deficiencies appeared in 65% of letters and CMC deficiencies in 51%, more often than efficacy or safety issues. Many trace to late-surfacing risks, unclear ownership, and gaps between development, manufacturing, and quality.
What is CMC readiness?
CMC readiness means chemistry, manufacturing, and controls data, validated processes, and GMP facilities are ready to support a regulatory filing and pre-approval inspection. It depends on process development, manufacturing, MSAT, QC, QA, regulatory, and supply chain working from one plan.
How can a biotech manufacturing team prepare for a pre-approval inspection?
Beyond mock inspections and document reviews, teams prepare by aligning functions on one integrated timeline, clarifying who owns each decision, bringing QA in early, and building consistent GMP habits so every team member tells the same accurate story.
Does High-Performance Science Teams™ help manage CDMO partners?
Yes. It builds a cross-functional external-manufacturing team with shared accountability and early-warning norms, so CDMO issues surface early instead of at batch release or in an inspection.
How do we start?
With the Science Team 360™, a confidential diagnostic that shows where alignment, decision rights, and accountability break down in your technical operations team.
Sources
- Dilek S., Woods R.H., Ballreich J., Moore T.J., Alexander G.C. “Deficiencies Delaying Prescription Drug Approvals by the U.S. Food and Drug Administration, 2020–2024.” Therapeutic Innovation & Regulatory Science 60(3):837–846 (2026) — https://doi.org/10.1007/s43441-026-00921-3
- Pharma Manufacturing, “FDA’s CRLs reveal 74% of applications rejected for quality, manufacturing issues” (July 2025; analysis of 202 CRLs, 2020–2024) — https://www.pharmamanufacturing.com/all-articles/article/55302937/fdas-crls-reveal-74-of-applications-rejected-for-quality-manufacturing-issues
- Guttman, H.M. Great Business Teams: Cracking the Code for Standout Performance (Wiley, 2008) — https://www.guttmandev.com/great-business-teams
Figures from third-party studies are cited as published. Cross-industry data is presented as directional for life science. Program outcomes described are targets teams track against their own Science Team 360™ baseline, not guaranteed results.